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Neurocognitive deficits remain a significant source of morbidity in survivors of cardiac arrest. We conducted a
literature review of treatment protocols designed to evaluate neurologic outcome and survival following global
cerebral ischemia associated with cardiac arrest. The search was limited to investigational therapies that were
implemented either during cardiopulmonary resuscitation or after return of spontaneous circulation in studies that
included assessment of impact on neurologic outcome. Given that complex pathophysiology underlies global brain
hypoxic ischemia following cardiac arrest, neuroprotective strategies targeting multiple stages of neuropathologic
cascades should promise to improve survival and neurologic outcomes in cardiac arrest victims. In Part II of this
review, we discuss several approaches that can provide comprehensive protection against global brain injury
associated with cardiac arrest, by modulating multiple targets of neuropathologic cascades. Pharmaceutical
approaches include adenosine and growth factors/hormones including brain-derived neurotrophic factor,
insulin-like growth factor-1 and glycine-proline-glutamate, granulocyte colony stimulating factor and estrogen.
Preclinical studies of these showed some benefit but were inconclusive in models of global brain injury involving
systemic ischemia. Several medical gases that can mediate neuroprotection have been evaluated in experimental
settings. These include hydrogen sulfide, hyperbaric oxygen and molecular hydrogen. Hyperbaric oxygen and
molecular hydrogen showed promising results; however, further investigation is required prior to clinical application
of these agents in cardiac arrest patients.
Keywords: Cardiac arrest, Global brain injury, Comprehensive neuroprotection, Model, Pharmaceutical, Hyperbaric
oxygen, Hydrogen sulfide, Hydrogen gasIntroduction
According to the 2013 update of Heart Disease and
Stroke Statistics from the American Heart Association
(AHA), out-of-hospital cardiac arrest (CA) has an overall
incidence of 359,400 yearly and a low 9.5% survival rate
[1]. Additionally, more than 200,000 adults have in-
hospital CA each year and only 23.9% of these patients
survive to hospital discharge [1]. For those patients who
do survive to hospital discharge, neurologic injury re-
mains a source of significant morbidity. Nearly 70% of
patients still have moderate to severe cognitive deficits* Correspondence: rapplegate@llu.edu
1Department of Anesthesiology, Loma Linda University School of Medicine,
11041 Campus Street, Loma Linda, CA, USA
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reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.at three months after CA [2]. The persistence of un-
favorable neurologic outcomes, despite advances in car-
diopulmonary resuscitation (CPR) prompted AHA to
emphasize brain injury in relation to cardiac arrest by
proposing “cardiopulmonary-cerebral resuscitation” in
its 2000 Guidelines for Cardiopulmonary Resuscitation
and Emergency Cardiovascular Care [3]. Therapeutic
strategies targeting brain injury after CA are thus an
important area for basic and clinical research. Over de-
cades, however, a host of putative neuroprotective strat-
egies failed to demonstrate clinical benefit except for
mild therapeutic hypothermia [4]. New neuroprotective
approaches are warranted in the setting of global brain
injury associated with CA.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tributing to global brain hypoxic ischemia following CA
have been summarized in Part I of this review. Whole body
ischemia/reperfusion injury and/or systemic inflammatory
responses increase the pathologic complexity of brain in-
jury following CA, which in turn increases the difficulty
and complexity in the search for an effective neuroprotec-
tive agent. In this context, a specific therapy targeting mul-
tiple stages of neuropathology cascades should provide
promise to improve survival and neurologic outcomes in
CA victims. Indeed, the successful translation of thera-
peutic hypothermia (TH) to CA patients is attributed to
the multiple neuroprotective effects of TH against global
brain ischemia [5].
Literature search method
A literature search was conducted of articles indexed in
Medline and published between 1980 and October 2013
using combination of keywords including “brain injury”,
“cardiac arrest”, “neuroprotection”, “cerebral protection”,
“cardiopulmonary resuscitation”, “global ischemia”,
“global cerebral ischemia”, and “global brain ischemia”
(Table 1). Bibliographies of relevant articles were cross-
referenced for pertinent articles. Articles were selected
for review if postulated mechanisms of neuroprotection
and some measure of neurologic outcomes were in-
cluded. Only neuroprotective strategies tested in animal
models relevant to global brain ischemia associated with
CA were reviewed. Case reports, pediatric studies and
articles not written in English were excluded. Studies of
therapies administered before CA were not included as
our goal was to investigate potential therapies to im-
prove neurologic outcome that can be employed in the
clinical setting (during or after CPR). Similarly, the
many studies related to neuroprotection from anestheticTable 1 Search terms used to perform literature search
Database Search terms
PubMed Brain injury
Cardiac arrest
Neuroprotection
Neuroprotection
Cerebral protection
Cardiopulmonary resuscitation
Global ischemia
Gglobal cerebral ischemia
Global brain ischemia
These terms were searched in
combinations as subject headings
and keywords simultaneously.
Articles were limited to those
printed or translated into Englishagents were not included, as administration of anesthetic
agents during or immediately after CPR may be impracti-
cal or associated with undesirable hemodynamic effects.
Due to the pathophysiologic differences between focal and
global cerebral ischemia, the extensive literature regarding
neuroprotective strategies in focal cerebral ischemia is ac-
knowledged but not included in this review. In this part, a
total of 17 preclinical studies were reviewed. We focus on
several strategies that demonstrate comprehensive neuro-
protective mechanisms evaluated in the setting of whole
body and global brain ischemia associated with CA. Due
to the limited numbers of publications in this area, we in-
cluded pre-clinical studies using animal models of global
brain injury involving bilateral carotid occlusion along
with systemic hypotension.
Review
In addition to global brain ischemia and reperfusion, CA
and resuscitation are associated with whole body ische-
mia/reperfusion injury and/or systemic inflammatory re-
sponses. These processes increase the pathological
complexity of brain injury following CA. Therapeutic in-
terventions targeting multiple stages of neuropathologic
cascades that have been investigated can be separated
into PHARMACEUTICAL APPROACHES and GAS-
MEDIATOR APPROACHES (Table 2).
Pharmaceutical approaches
Adenosine
Adenosine was proposed in the late 1980’s to be an en-
dogenous neuroprotective molecule with multiple func-
tions [6]. Effects of adenosine and its receptor agonists
include reducing the release of excitotoxic neurotransmit-
ters, vasorelaxation, anti-inflammatory effects, reduction
of metabolism, scavenging free radicals and moderate re-
duction of brain temperature [6,7]. Only one pre-clinical
study evaluated its treatment effects in the setting of glo-
bal brain injury associated with CA [8]. In a rat model of
CA and CPR, post-ischemic administration of adenosine
(7.2 mg/kg) was associated with a transient increase in
brain total adenylates, hypothermia, increased post-
ischemia brain blood flow and reduced brain edema and
delayed CA1 neuronal loss in the hippocampus [8].
In the brain, adenosine acts as a neurotransmitter
through activation of four specific G-protein-coupled ad-
enosine (A) receptors: A1, A2A, A2B and A3 receptors
[9]. The A1 receptor mediates neuroprotection, mostly by
blockade of Ca2+ influx, which results in inhibition of
glutamate release and reduction of glutamate excitatory
effects at a postsynaptic level [10]. Unfortunately, select-
ive activation of A1 receptors as a therapeutic approach
for brain injury was hampered by major cardiovascular
side effects such as bradycardia and hypotension [6,9].
Given that selective activation of A2A and A3 receptors
Table 2 Summary of comprehensive neuroprotective strategies for global cerebral ischemia associated with cardiac arrest
Therapy Proposed mechanism Study subject Blind Placebo
control
Random
assignment
Delivery route Effect: Outcomes evaluated
Positive
Negative
Neutral
Pharmaceutical approaches
Adenosine [8] Blockade Ca2+ influx
[10] Hypothermia [8]
Rats Not mentioned Yes Yes Intravenous Positive Survival, regional blood
flow, brain edema,
metabolite assay,
neurohistopathology,
temporalis muscle
temperature
BDNF [14] Up regulate Bcl-2, suppress
TNF-alpha, increase IL-10,
reduce excitotoxicity,
promote neural regeneration
and axonal sprouting/
synaptogenesis [11]
Rats Not mentioned Yes Not mentioned Intracerebro-
ventricular
Neutral Survival, neurologic
function, neurohistopathology
IGF-1/GPE [19,21] Anti-apoptosis, modulation
of BBB permeability and
neuronal excitability [17]
Rats Not mentioned Yes Yes Intravenous [19] Positive when
combined with TH [19]
Neurologic function [19]
HIF-1 alpha activation [18] Intracerebro-
ventricular [21]
Short-term: Positive;
Long-term: Neutral [21]
Neurohistopathology [18,21]
G-CSF [25,26] Anti-apoptosis, anti-
inflammation and
enhance neurogenesis [23]
Rats Not mentioned Yes Yes [25] Subcutaneous [25] Positive [25] Survival, neurologic function,
neurohistopathology [25,26]
Not mentioned
[26]
Intracerebro-
ventricular [26]
Long-term: Negative
[26]
p-STAT3, p-AKT1/2/3
and p-ERK1/2 [25]
Estrogen [30-32] Promote neuronal survival
and neurogenesis [29]
Mice Not mentioned
[30,31]
Yes Yes Intravenous [30,31] Positive Neurological function
[31] Neurohistopathology [30-32]
Increase expression
of SK2 [32]
Yes [32] Subcutaneous
[31,32]
Small-conductance
calcium-activated
potassium (SK2 and SK3)
channel transcripts,
electrophysiology [32]
Reduce excitoxicity [33,34]
Gas-mediator approaches
H2S [41-44] Increase level of
antioxidant glutathione
and/or scavenging oxygen
species, anti apoptosis and
anti-inflammation [37-39]
Mice [41-43] Not mentioned
[41,42,44]
Yes Not mentioned Intravenous Positive when
delivered at or prior
to CPR initiation [41-43]
Survival, neurologic function,
neurohistopathology [41-44]
Open KATP chanel [35-37] Pigs [44] Yes [43] Neutral when delivered
10 min after CPR [41]
Myocardial function,
serum nitrite/nitrate levels
and hydrogen peroxide
level, cardiac
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Table 2 Summary of comprehensive neuroprotective strategies for global cerebral ischemia associated with cardiac arrest (Continued)
mitochondrial
swelling [41]
Enhance NMDA
receptors [38]
Negative [44] Diffusion weighted
imaging and MMP-9
activity [42]
Cardiac output, heart
rate and pulmonary
arterial pressure [44]
HBO [52,53] Attenuation of oxidative
and inflammatory injury,
inhibition of apoptosis,
enhance neurogenesis
[47,48]
Dogs [52] Not mentioned Yes Yes [52] Inhaled Positive Neurologic function [52]
Neurohistopathology [52,53]
Rats [53] Not mentioned
[53]
Oxygen extraction ratio
and cerebral oxygen
delivery/utilization [52]
Expression of Nogo-A/B,
Nogo receptors and
RhoA expressions [53]
H2 [57,58] Anti-oxidant, anti
inflammation and
anti-apoptosis [55,56]
Rats [57] Not mentioned Yes Yes Inhaled [57] Positive Survival, neurologic function,
neurohistopathology [57,58]
Rabbit [58] Intraperitoneal [58] Myocardial function,
cardiomyocyte
degeneration, lung
edema and systemic
inflammatory response [57]
Plasma 8-OHDG
and MDA level [58]
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and cell death, respectively, development of selective
antagonists targeting A2A and A3 may offer a possible
treatment for brain disorders via anti-excitoxicity, anti
inflammation and anti-apoptosis mechanisms [10,11].
Therapeutic applications of discrete adenosine ligands
need to be further explored in the setting of global brain
ischemia following CA.
Growth factors/hormones
Under focal ischemic conditions in the brain, adminis-
tration of several types of exogenous growth factor/hor-
mones has been shown to be neuroprotective. Limited
animal studies evaluated their effects in global brain is-
chemia secondary to CA. However, the neuroprotective
effects were not as robust as that found in cerebral is-
chemia that does not concurrently involve complete sys-
temic circulatory stasis. Furthermore, a short half-life
and a low rate of transport through the blood brain bar-
rier (BBB) could challenge clinical applications of growth
factor/hormones for brain protection.
1. Brain-derived neurotrophic factor (BDNF)
BDNF is a neurotrophic factor in the nerve growth
factor family. It acts as a potent neuronal survival
modulator through the tropomyosin-related kinase
receptor type B [12]. The neuroprotective role of
BDNF has been shown in ischemic injury including
focal brain ischemia, hypoxic-ischemia and global
brain ischemia induced by four vessels occlusions
[12,13]. The multiple protective roles of BNDF
against ischemic brain injury may involve 1)
anti-apoptosis by up-regulating B-cell lymphoma-2
(Bcl-2) and inhibiting intracellular calcium overload;
2) anti-inflammation by suppressing pro-
inflammatory tumor necrosis factor (TNF)-α
expression while increasing anti-inflammatory
interleukin (IL)-10 expression; 3) attenuating
neurotoxicity mediated by N-methyl-D-aspartate
(NMDA) and glutamate; 4) promoting neural
regeneration and increasing axonal sprouting and
synaptogenesis as well as angiogenesis [12].
However, BDNF failed to provide neurological benefit
in a rat model of 6 minute CA and CPR [14].
Neurologic deficits and neurohistopathology at 1, 3
and 7 days post-CA were not different between
BDNF treated and placebo treated rats.
2. Insulin-like growth factor-1 (IGF-1) and
glycine-proline-glutamate (GPE)
IGF-1 participates in somatic and vascular growth,
glucose hemostasis and brain development [15,16].
By binding to its specific receptor and binding
proteins, IGF-1 exerts pleiotropic neuroprotection
including potent antiapoptotic properties, modulationof BBB permeability and neuronal excitability [17].
Activation of hypoxia-inducible factor (HIF)-1α
might also be part of the mechanism underlying
IGF-1 promoted cell survival after cerebral ischemia
[18]. In a rat model of bilateral carotid occlusion and
systemic hypotension, the combination therapy of
IGF-1 and hypothermia protected the brain against
global ischemic injury. After 8 minutes of untreated
global brain ischemia, at the onset of reperfusion one
of three treatment regimens was initiated:
intravenous (IV) administration of 0.6 U/kg IGF-1
alone; hypothermia (32˚C for 4 h) alone; or
combined IGF-1 with hypothermia. Only IGF-1
combined with hypothermia preserved hippocampal
CA1 structure and improved neurological function
compared to non-treated rats [19].
GPE is a bioactive cleavage product from N-terminal
IGF-1 and is also protective against ischemic brain
injury [20]. The multiple mechanisms of GPE may
be modulation of inflammation, promotion of
astrocytosis, inhibition of apoptosis and vascular
remodeling [20]. The effects of IGF-1 and GPE were
compared in a rat model of CA and CPR [21]. Rats
were randomized to receive intracerebroventricular
(ICV) IGF-1, GPE, or placebo as a constant infusion
for up to 7 days post-ischemia. Neurohistopathologic
staining of the CA1 region of the hippocampus was
performed at 3, 7 and 14 days. The early significant
reduction in the number of apoptotic cells was only
observed in the GPE group at 3 days, but this did not
persist to 7 or 14 days. From a translational point of
view, GPE is a small neuropeptide that can pass BBB
easily, thus giving advantages over growth factors in
the treatment of brain injury. Nevertheless, it
requires a continuous IV infusion to maintain stable
central uptake due to the extremely short half-life
of GPE [20].
3. Granulocyte colony stimulating factor (G-CSF)
G-CSF is an endogenous peptide hormone of the
hematopoietic system that has been evaluated in
clinical trials for ischemic stroke [22,23]. By binding
to G-CSF receptors in the brain, G-CSF has
neuroprotective effects through anti-apoptosis and
anti-inflammation as well as through enhancing
neurogenesis [24]. A rat model of global brain
ischemia induced by 2-vessel occlusion with
hemorrhagic hypotension demonstrated the
neuroprotective effect of G-CSF [25]. In a rat CA
and CPR model, ICV administration of G-CSF
(7 or 14 days), however, did not benefit survival,
neurobehavioral testing or histopathology over
14 days post-resuscitation [26]. Instead, application
of G-CSF increased neuronal damage at 14 days
after CA [26].
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Estrogen can bind to two classic nuclear receptors,
namely, estrogen receptor (ER)-α and ER-β, to pro-
duce physiologic and neuroprotective effects [27]. A
number of studies have demonstrated that estrogen
is neuroprotective in brain injury [27,28]. Multiple
cellular pathways of cell protection have been
associated with estrogen [27]. These involve
extracellular signal-regulated kinase/mitogen
activated protein kinase signaling and cross talking
with IGF-1, which leads to cAMP responsive element
binding protein phosphorylation and subsequent
neuronal survival and neurogenesis following
ischemic insult [29].
Several preclinical studies were performed to
evaluate the neuroprotective effect of estrogen
against global brain ischemia. In a mouse model of
CA (10 minutes) and CPR, different single IV
injection dosages of estrogen (0.5, 2.5, 12.5, 25, or 50
micrograms) acutely after resuscitation did not
benefit histopathology within hippocampi at 3 days
post-resuscitation [30]. But the lowest dose of
estrogen resulted in attenuated neuronal injury in the
rostral and caudal caudoputamen regions. In a
follow-up study, the same group demonstrated the
neuroprotection of long-term administration ofFigure 1 Neuroprotective mechanisms of gas-mediated approaches after r
hyperbaric oxygen (HBO) and hydrogen gas (H2) exert anti-oxidant, anti-inflamm
signaling pathways. Such comprehensive brain protection leads to improved ou
cardiac arrest.estrogen, which was most likely mediated by ER-β
[31]. They first randomized male mice to receive
17β estradiol (E2, IV loading dose of 0.5 or 2.5
micrograms followed by 12.6 micrograms
administered by subcutaneous implant for 3 days) or
placebo after 10 minutes of CA followed by CPR. E2
at low or high dose had a neuroprotective effect on
the rostral and caudal caudoputamen, but no effects
in the hippocampal CA1 region. Neurologic
functional recovery was only significant on day 3
with the higher loading dose. Secondly, they tested
estrogen receptor (ER) agonist specific for the α or β.
The ER-β, but not ER-α, agonist showed improved
neuronal survival in striatum and hippocampal CA1
compared to placebo.
Independent of ER-α and-β, G protein-coupled
estrogen receptor 1/G-protein-coupled receptor 30
(GPER1/GPR30) is a recently identified membrane
receptor that binds estrogen with high affinity [32].
In a mouse model of CA, chronic treatment of male
mice with GPR 30 agonist G1 decreased neuronal
injury to an extent comparable to estrogen treatment.
The increased expression of small-conductance
calcium-activated potassium channel 2 (SK2) by G1
could protect neurons from ischemic injury [32].
Other studies also suggest that GPR30 is involved inesuscitation from cardiac arrest. Hydrogen sulfide (H2S),
ation and anti-apoptosis effects through regulation of variable
tcomes in the setting of global brain injury associated with
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NMDA receptor 2B (NR2B)-containing NMDA
receptors, thus reducing excitoxicity [33,34].
Developing agonists specifically targeting GPR may
provide a promising pharmaceutical approach for
neuroprotection.Gas-mediator approaches
Gas-mediators exert whole brain protection through com-
prehensive and complementary mechanisms (Figure 1).
Favorable biomembrane permeability renders them at-
tractive alternatives for treatment of global ischemia fol-
lowing CA.
Hydrogen sulfide
Hydrogen sulfide (H2S) was originally known as a toxic
gas and environmental pollutant. However, there has
been growing interest in the potential role of H2S as an
endogenous signaling molecule: a third gasotransmitter
[35,36]. By opening ATP-sensitive potassium (KATP) chan-
nels, endogenous H2S acts as a vasorelaxant [35-37]. A
number of preclinical studies suggested exogenous low
concentration H2S protects cells from oxidative stress by
increasing levels of glutathione (a cellular major and
potent antioxidant) and/or directly scavenging oxygen
species [38]. It also exerts anti-apoptotic and anti-
inflammation effects [37,39]. In addition, H2S facilitates
the induction of hippocampal long-term potentiation by
enhancing the activity of NMDA receptors [40]. In animal
studies of global ischemia brain injury, H2S or H2S donors
provided mixed results. Although H2S can protect against
inflammation, it may also be involved in intracellular cal-
cium overload and worsen secondary neuronal injury
[35,36,39]. These data suggested that H2S may have bene-
ficial and/or detrimental effects depending on what patho-
logical state and/or what phase in a certain pathological
state it is administered.
Sodium sulfide, sodium hydrogen sulfide
In mouse model of CA and CPR, administration (IV)
of sodium sulfide (Na2S, a hydrogen sulfide donor)
0.55 mg/kg at CPR initiation significantly improved sur-
vival and neurological deficits at 24 hours [41]. It also sig-
nificantly decreased apoptosis in the hippocampus, and
prevented myocardial dysfunction [41]. Delaying Na2S ad-
ministration to 10 minutes after CPR was also investigated
but did not confer the same advantages as when adminis-
tered at CPR initiation. No formal long-term analysis was
performed in this study, but pilot studies show a signifi-
cant long-term survival advantage in treatment group
mice. A similar study investigated the mechanism by
which by sodium hydrogen sulfide (NaHS; another hydro-
gen sulfide donor) conferred benefit [42]. Study methods
were similar to Na2S studies, but data was collected over10 days and abnormal water diffusion in the brain was
investigated using hyperintense diffusion-weighted im-
aging. Mice treated with NaHS had significantly im-
proved 10-day survival, neurological outcome, and
reduced brain water diffusion. Results differed in a
mouse study utilizing a very similar protocol [43]. At
CPR initiation, Na2S was administered (0.5 mg/kg IV
bolus) and continued as an infusion (1 mg/kg/hr) for
6 hours. The only significant difference was better
neurological function scoring at 3 days in mice treated
with Na2S. No other differences were seen between
groups with respect to neurological function or
neurohistopathology.
In contrast, researchers using a pig model of pro-
longed CA and CPR reported detrimental effects. Na2S
(1 mg/kg or 0.3 mg/kg) injection and infusion given at
1 min after starting CPR did not improve initial resusci-
tation success. It further compromised early postresusti-
cation hemodynamics by reducing cardiac output, heart
rate and pulmonary arterial pressure [44]. Such deleteri-
ous outcome was more significant in the high dose Na2S
group. H2S mediated cerebral ischemia damage has been
attributed to increased excitotoxicity through activating
NMDA receptors in experimental focal ischemia [45] or
due to its vasodilatation effect [44]. These conflicting re-
sults may be due to differences in drug administration
time between the rodent model (at CPR initiation) and
porcine model (1 minute after starting CPR). It suggests
that the temporal window of opportunity for improving
the outcome of CA/CPR is relatively narrow and may re-
quire delivering Na2S immediately after reperfusion.
This feature echoes a previous study of ischemic post-
conditioning that found the delay of onset of post-
conditioning by only 1 minute aborts protection in rabbit
heart [46].
Hyperbaric oxygen (HBO)
HBO at low pressure (within 3 ATA) has been shown to
ameliorate brain injury in a variety of animal models in-
cluding focal cerebral ischemia, neonatal hypoxia–ischemia
and subarachnoid hemorrhage [47]. Possible neurotoxicity
was only found when HBO was applied at high pressure
(>3ATA) and long duration [47]. Adverse effects include
increased spontaneous respiratory rate that can lead to ar-
terial hypocapnia with reduced cerebral blood flow, in-
creased lipid peroxidation and seizures [47]. The multiple
mechanisms of HBO include enhancing tissue oxygen-
ation/metabolism, reduction of oxidative stress, inflamma-
tion modulation, and inhibition of apoptosis as well as
enhancing neurogenesis [47,48]. It suggests low pressure of
HBO may provide a promising neuroprotective strategy
for CA patients favoring neurological function recovery.
Neuroprotective effects of HBO therapy have been re-
ported in animal models of global brain ischemia induced
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Elliott’s B solution into the subarachnoid space [50] and 4-
vessel occlusion [51].
Positive results were consistently observed in two stud-
ies using a global brain ischemia model involving whole
body ischemia. In a dog model of CA, animals were ran-
domized to control or HBO after CA and resuscitation
[52]. HBO was administered at 2.7 ATA for 60 minutes
starting 1 hour after ROSC. The functional status of the
dogs was significantly better and neuronal damage was
significantly less in the HBO group at 1 day after ROSC.
Cerebral oxygen extraction ratio was also significantly less
in the HBO group. In a rat model of global brain ischemia
with hypotension, HBO (3 ATA) applied at 1 h after ische-
mia for total of 2 h significantly reduced neuronal death in
the CA1 region of the hippocampus and the cortex [53].
Additional preclinical studies using clinically relevant
CA models are needed to establish the optimal dose and
time for treatment as well as the safety of applying HBO
treatment following ROSC, particularly when intensive
care is required.
Molecular hydrogen (H2)
Molecular hydrogen has previously been proposed as a
novel selective hydroxyl radical and peroxynitrite scaven-
ger in the treatment of focal brain ischemia [54]. Emerging
evidence has demonstrated its protective a role in a variety
of diseases through anti-oxidant, anti-inflammation and
anti-apoptotic effects [55,56]. There is no risk of combus-
tion at concentrations less than 4% H2 [56]. In two animal
models of global brain ischemia, hydrogen gas or hydro-
gen rich saline benefitted overall outcome after CA, in-
cluding neurological function [57,58]. The protective
effects have been shown to be comparable to therapeutic
hypothermia [57].
Rats underwent 5 minutes of CA followed by CPR and
were randomized to sham, control (ventilation with 98%
O2 + 2% N2), therapeutic hypothermia (TH), hydrogen
gas (H2, ventilation with 98% O2 + 2% H2), or TH +H2
groups [57]. Twenty-four and seventy-two hour survival
was significantly improved in rats treated with H2, H2 +
TH, or TH compared to controls. At 24 and 48 hours,
the H2, H2 + TH, and TH groups were significantly bet-
ter than the control group, and the H2 + TH group was
significantly better than the TH and H2 groups alone.
Systemic inflammatory response measured at 2 hours
post ROSC showed significantly reduced levels of IL-6 in
H2 and H2 + TH groups compared to control or TH
groups. Other significant effects seen with the H2 gas in-
cluded maintaining low left ventricular end diastolic
pressure during the first 2 hours after ROSC when com-
pared to controls, decreased lung edema at 24 hours
post-CA (levels same as sham rats), and attenuation of
cardiomyocyte degeneration.In rabbits subjected to CA followed by CPR, intraperito-
neal injection of H2 rich saline or placebo was done at
CPR initiation [58]. Animals were assigned to sham (no
CA); CA; CA + low dose H2 (10 ml/kg; CA +H2 group 1);
and CA + high dose H2 rich saline (20 ml/kg; CA +H2
group 2). Intraperitoneal H2 rich saline (low and high
dose) significantly improved 72-hour survival, reduced
neuronal injury, and reduced plasma oxidative markers.
Neurologic functional recovery was significantly improved
only with 20 ml/kg H2 compared to controls at 72 hours.
H2 is cost-effective and has low toxicity with little
drug-drug interaction. These features could make H2 ad-
ministration an ideal neuroprotection approach that
could be implemented during CPR and/or after ROSC.Conclusions
Comprehensive neuroprotective strategies benefit global
brain ischemia associated with cardiac arrest by targeting
oxidative stress, cell apoptosis and inflammatory responses.
Based on limited preclinical findings, gas-mediator strat-
egies, particularly, HBO (within 3 ATA) and molecular H2,
have shown promise for improving survival and neurologic
outcomes when implemented either during or immediately
after CPR. Such comprehensive brain protective therapies
may provide advantages over selective treatment strategies
that have been developed for global brain ischemia over
the past few decades. To date, no clinical studies have been
conducted to test these approaches in patients with global
brain ischemia. Translational research is needed to further
elucidate fundamental neuroprotective mechanisms and
effective treatment protocols prior to clinical applications
in the future.
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